Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes.
Joined November 2016
- Tweets 917
- Following 285
- Followers 827
- Likes 106
861 Photos and videos
Pinned Tweet
Feb 17
Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month.
Learn more: ow.ly/svKn50YgYXM
3
8
1,309
On Investor Day, our leadership team and key opinion leaders will share the progress, priorities, and our momentum shaping the future of retinal disease innovation. Join us June 17 to hear about our mission to redefine the retina experience: ow.ly/lObf50Z9x0F
1
2
81
Jun 10
At Clinical Trials at the Summit, we'll share analyses from our landmark SOL-1 Phase 3 superiority clinical trial in wet AMD and HELIOS study in diabetic retinopathy.
At Ocular, we're continuing our mission to redefine the retina experience.
Learn more: ow.ly/9KNX50Z9G9h
2
4
4,090
Jun 2
We’re thrilled to be joined by Arshad Khanani, MD, Darius Moshfeghi, MD, and Lejla Vajzovic, MD, FASRS for our Investor Day, where they’ll share perspectives on the current retinal disease landscape.
Learn more about what we will discuss on June 17: ow.ly/yW4E50Z6BMh
2
117
May 29
What could sustained disease control mean for future management of wet AMD? Retina leaders share how maintaining stable vision and retinal anatomy over time could help address the challenges associated with current treatment approaches.
Explore more: ow.ly/4tyY50Z2Xmr
2
103
May 27
At @RWCRetina, retina leaders discussed durability's role in the management of wet age-related macular degeneration, focusing on how longer-acting treatments may reduce treatment burden, support disease control, and improve outcomes.
Explore more: ow.ly/yoXv50Z2Xk9
2
111
May 22
Retina leaders at @RWCRetina discussed the future of wet AMD care, exploring the importance of clinical trial design that evaluates durability, meaningful endpoints, and the potential to improve long-term outcomes for patients.
Explore more: ow.ly/rFVk50Z2Xec
3
129
May 21
At the Royal College of Ophthalmologists Congress, Adnan Tufail, MBBS, MD, Darius M. Moshfeghi, MD, and Dilsher Dhoot, MD spotlighted new analyses related to our landmark SOL-1 Phase 3 clinical trial.
Learn more: ow.ly/Sv6U50Z2o5s
#RetinaRedefined
2
3
140
May 21
Our Executive Chairman, President, and CEO Pravin Dugel, MD will join @Stifel’s Ophthalmology Conference to discuss the future of retinal disease treatment and insights from our landmark SOL-1 Phase 3 superiority clinical trial in wet AMD.
Learn more: ow.ly/pJ0M50Z1Hoi
2
113
May 20
Investor Day is almost here, and we’re excited to connect on June 17 at 2:00 PM ET in New York City. We’ll share updates on our strategy, momentum across the business, and commitment to advancing the future of retina care through innovation.
Learn more: ow.ly/t3Hw50Z1OYC
1
5
234
May 19
At @RetinaWCongress, our team was proud to share data from our landmark SOL-1 Phase 3 superiority clinical trial in wet age-related macular degeneration with the global retina community.
Learn more about our mission to redefine the retina experience: ow.ly/sFiV50Z1H5I
1
2
3
173
May 15
Patricio Schlottmann, MD presented on the landmark SOL‑1 Phase 3 clinical trial in wet AMD at @ARVOinfo. He highlighted how clinical trial design may help inform the future of durability and sustained disease control in retinal care.
Learn more: ow.ly/VfzY50Z08Jg
1
2
175
May 15
This content discusses an investigational drug, OTX‑TKI (AXPAXLI™), currently in development. Its safety and efficacy have not been established, and it is not approved for marketing by the FDA or any other health authority.
2
86
May 14
At @ARVOinfo, Andrew Moshfeghi, MD shared findings from a real-world analysis of anti‑VEGF treatment utilization and vision outcomes in wet AMD, focusing on how treatment burden may contribute to suboptimal long‑term visual outcomes. Learn more: ow.ly/ozJk50YYgUQ
2
130
May 13
Ocular’s Chief Development Officer Peter Kaiser, MD will present at @RetinaWCongress Unplugged. He plans to discuss our novel approach across clinical trial development as we aim to improve long-term outcomes.
Visit us at booth 2 and learn more at ow.ly/ivM350YWIhZ.
2
93
May 13
At @BankofAmerica’s Global Healthcare Conference, our Executive Chairman, President, and CEO Pravin Dugel, MD shared updates on our clinical programs in wet AMD and diabetic retinopathy.
Learn more about our mission to redefine the retina experience: ow.ly/Wv6450YYT0z
2
122
May 12
Christina Weng, MD, MBA, FASRS presented IRIS registry findings that showcased how early vision improvements with anti‑VEGF therapy may decline over time for patients with wet AMD at @ARVOinfo.
Learn more: ow.ly/WZrx50YYeQx
2
114
May 11
We’re excited for @RetinaWCongress and to share data from our SOL-1 Phase 3 trial in wet age-related macular degeneration. We look forward to sharing how we’re working to redefine the retina experience.
Visit us at booth 2 and learn more: ow.ly/PChz50YWIwj
1
3
125
May 11
The @BankofAmerica Global Healthcare Conference kicks off tomorrow, where our Executive Chair, President, and CEO Pravin Dugel, will discuss our clinical trial programs and key insights around our SOL-1 Phase 3 trial data.
Learn more: ow.ly/s96P50YWIoH
1
3
110
May 8
Our team enjoyed engaging with the retina community and continuing conversations around our landmark SOL-1 Phase 3 trial in wet age-related macular degeneration at @ARVOinfo, reflecting our commitment to advancing retinal disease care.
Learn more: ow.ly/TaFu50YWHzO
2
118
May 5
Today, we shared our Q1 2026 earnings, highlighting updates across our clinical trials in retinal disease. This progress highlights our focus on advancing potential long-acting treatment options for retinal disease.
Learn more: ow.ly/t6io50YUYt3
#RetinaRedefined
1
2
188